| Name | TM-25659 |
| Description | TM-25659 is a modulator of transcriptional co-activator with PDZ-binding motif (TAZ), with anti-osteoporotic and anti-obesity activities. |
| In vitro | Treatment with TM-25659 (2, 10, 20, 100 μM) dose-dependently enhances nuclear TAZ localization and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ. Osteogenic gene expression is enhanced by TM-25659 (2, 10, 50 μM) and thereby osteoblast differentiation is increased[1]. |
| In vivo | In vivo, TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss and decreases weight gain in an obesity model. The plasma concentration of TM-25659 declines with an approximate t1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L/(h×kg) and the volume of distribution at steady-state (1.91 L/(h×kg)) is larger than the volume of total body fluids[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (199.76 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.99 mM), Sonication is recommended.
|
| Keywords | TM-25659 | TM25659 | TM 25659 | TAZ |
| Inhibitors Related | AICAR | MY-1076 | YAP-TEAD-IN-3 | Verteporfin | DC-TEADin02 | MSC-4106 | Thiostrepton | OPN-9652 | VT107 | VT104 | alpha-Ionone | MYF-01-37 |
| Related Compound Libraries | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max |
United States
